Discover how evolving HER2 science and testing recommendations are transforming care for patients with non small cell lung cancer. This meeting will equip advanced practice providers, nurses, and multidisciplinary oncology teams to navigate HER2 alterations, apply comprehensive testing strategies, and integrate emerging HER2-targeted therapies into clinical practice. Participants will also explore practical approaches to multidisciplinary coordination, toxicity management, patient-centered decision-making, and equitable access to biomarker-driven care. Upon completion of this activity, the participants should be able to: Explain the role of HER2 biology and appropriate testing methods in thoracic oncology. Apply current guidelines to HER2 biomarker testing, diagnosis, and treatment selection. Implement multidisciplinary strategies that improve coordination and communication across the care team. Develop individualized approaches to toxicity management and patient-centered care. Identify strategies to address barriers and improve equitable access to biomarker-driven oncology care.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 1775 N. Sherman St
Pricing
Priced per course
12 free · 1 with a listed price · based on 21 courses listed here
Collected from the provider’s public pages · source
Top 6 courses
-
-
-
2026 WCLC Credit Claim Extended
59.5 Credits
-
-
2026 WCLC Credit Claim Live
59.5 Credits
-
- No reviews yet. Be the first to share yours.
- Enduring / On-demand
- Credit · Up to 1 credit
- MOC · Up to 1 point
- Fee · varies
- Commercial Support
-
Available fromOct 18, 2026
-
Last day to claim creditJan 1, 2028 1 year left
-
PRIME Education, Inc. (PRIME®) Optimizing HER2 Assessment and Treatment in Advanced NSCLC: From Guidelines to the Clinic
-
University of Chicago School of Medicine Out-of-the-Box Solutions for Building Clinical Capacity in Community Settings to Improve Standardized ERBB2 (HER2) Testing in NSCLC
-
Answers in CME Inc. (AiCME) Beyond the Biomarker: Bridging Patient Voices and Precision Care in HER2-Mutant NSCLC
-
International Association for the Study of Lung Cancer 2026 IASLC CT Screening and Early Detection Symposium
-
International Association for the Study of Lung Cancer Best of ACLC 2025
-
International Association for the Study of Lung Cancer The Role of Molecular Tumor Boards in Modern Oncological Practice
